Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the business of producing, developing, and marketing a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporin segments.
Lupin Ltd. CMP is 1621.35. The positive aspects of the company are Company with Low Debt, Annual Net Profits improving for last 2 years, Company with Zero Promoter Pledge, FII / FPI or Institutions increasing their shareholding and Efficient in managing Assets to generate Profits. The Negative aspects of the company are Declining Net Cash Flow : Companies not able to generate net cash, MFs decreased their shareholding last quarter and Promoter decreasing their shareholding.
Entry can be taken after closing above 1636. Targets in the stock will be 1657 and 1677. The long-term target in the stock will be 1700 and 1728. Stop loss in the stock should be maintained at Closing below 1545 or 1497 depending on your risk taking ability.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.